Fetal microchimerism in kidney biopsies of lupus nephritis patients may be associated with a beneficial effect.

INTRODUCTION: Microchimeric male fetal cells (MFCs) have been associated with systemic lupus erythematosus, and published studies have further correlated MFC with lupus nephritis (LN). In the present study, we evaluated the frequency of MFC in the renal tissue of patients with LN. METHODS: Twenty-seven renal biopsies were evaluated: Fourteen were from women with clinical and laboratory findings of LN, and thirteen were from controls. Genomic DNA was extracted from kidney biopsies, and the male fetal DNA was quantified using real-time quantitative polymerase chain reactions for the detection of specific Y chromosome sequences. RESULTS: MFCs were detected in 9 (64%) of 14 of patients with LN, whereas no MFCs were found in the control group (P = 0.0006). No differences in pregnancy history were found between patients with LN and the control group. Significantly higher amounts of MFCs were found in patients with LN with serum creatinine ≤1.5 mg/dl. Furthermore, women with MFCs had significantly better renal function at the time of biopsy (P = 0.03). In contrast, patients with LN without MFCs presented with more severe forms of glomerulonephritis (World Health Organization class IV = 60% and class V = 40%). CONCLUSIONS: Our data indicate a high prevalence of MFCs in renal biopsy specimens from women with LN, suggesting a role for MFCs in the etiology of LN. The present report also provides some evidence that MFCs could have a beneficial effect in this disease.

Effect of stem cells seeded onto biomaterial on the progression of experimental chronic kidney disease.

Different routes for the administration of bone marrow-derived cells (BMDC) have been proposed to treat the progression of chronic renal failure (CRF). We investigated whether (1) the use of bovine pericardium (BP) as a scaffold for cell therapy would retard the progression of CRF and (2) the efficacy of cell therapy differently impacts distinct degrees of CRF. We used 2/3 and 5/6 models of renal mass reduction to simulate different stages of chronicity. Treatments consisted of BP seeded with either mesenchymal or mononuclear cells implanted in the parenchyma of remnant kidney. Renal function and proteinuria were measured at days 45 and 90 after cell implantation. BMDC treatment reduced glomerulosclerosis, interstitial fibrosis and lymphocytic infiltration. Immunohistochemistry showed decreased macrophage accumulation, proliferative activity and the expression of fibronectin and α-smooth muscle-actin. Our results demonstrate: (1) biomaterial combined with BMDC did retard the progression of experimental CRF; (2) cellular therapy stabilized serum creatinine (sCr), improved creatinine clearance and 1/sCr slope when administered during the less severe stages of CRF; (3) treatment with combined therapy decreased glomerulosclerosis, fibrosis and the expression of fibrogenic molecules; and (4) biomaterials seeded with BMDC can be an alternative route of cellular therapy.

Tetanus-induced acute kidney injury in a renal transplant recipient.

A 48-year-old renal transplant recipient who developed tetanus 6 years after transplantation is described. His immunosuppressive protocol was mofetil mycophenolate, sirolimus, and prednisone. The patient presented symptoms of severe tetanus with autonomic dysfunction, requiring ICU care and mechanical ventilation. His clinical course was marked by development of tetanus-induced acute kidney injury and sepsis. He was discharged after 37 days of hospitalization with recovered renal function. Tetanus is a preventable disease associated with a high fatality rate. Its treatment is difficult and requires specialized and intensive care. This case highlights the crucial importance of following adequate immunization guidelines in transplant recipients.

Descompensaçäo cardíaca pós-intoxicaçäo exógena por estricnina: relato de caso / Cardiac descompensation from exogenous intoxication by strychnine: case report

Apresentamos o caso de um paciente intoxicado por estricnina que evoluiu com Insuficiência Cardíaca Congestiva diagnosticada através de ecocardiograma e parâmetros hemodinâmicos conseguidos através de cateter de Swan-Ganz. A intoxicaçao por estricnina nao é comumente encontrada devido à proibiçao de sua comercializaçao, especial atençao tem sido dada a esta droga devido ao seu uso na manufatura de drogas como a cocaína. Alguns autores mostram que a estricnina age sobre centros vasomotores alterando pressao arterial durante as convulsoes, outros mostraram arritmias durante as convulsoes, mas nao comprovaram a existência de cardiotoxidade pela estricnina. A monitorizaçao hemodinâmica foi de bastante auxílio neste caso nao só no sentido de guiar a terapêutica mas também no diagnóstico diferencial do edema pulmonar que, em se tratando de paciente hígido e jovem poderia facilmente ser rotulado como edema "nao cardiogênico". Embora a intoxicaçao por estricnina seja de altíssima mortalidade, com o suporte hemodinâmico e respiratório adequado proporcionamos uma recuperaçao total do paciente, sem seqüela neurológica, renal e pulmonar.